

## A Novel *SCN5A* Gain-of-Function Mutation M1875T Associated With Familial Atrial Fibrillation

Takeru Makiyama, MD, PHD,\* Masaharu Akao, MD, PHD,\* Satoshi Shizuta, MD,\* Takahiro Doi, MD,\* Kei Nishiyama, MD,\* Yuko Oka, MD,† Seiko Ohno, MD, PHD,\* Yukiko Nishio, MD,\* Keiko Tsuji, MS,† Hideki Itoh, MD, PHD,† Takeshi Kimura, MD, PHD,\* Toru Kita, MD, PHD,\* Minoru Horie, MD, PHD†

Kyoto and Otsu, Japan

<b>Objectives</b>	This study describes a novel heterozygous gain-of-function mutation in the cardiac sodium ( $\text{Na}^+$ ) channel gene, <i>SCN5A</i> , identified in a Japanese family with lone atrial fibrillation (AF).
<b>Background</b>	<i>SCN5A</i> mutations have been associated with a variety of inherited arrhythmias, but the gain-of-function type modulation in <i>SCN5A</i> is associated with only 1 phenotype, long-QT syndrome type 3 (LQTS3).
<b>Methods</b>	We studied a Japanese family with autosomal dominant hereditary AF, multiple members of which showed an onset of AF or frequent premature atrial contractions at a young age.
<b>Results</b>	The 31-year-old proband received radiofrequency catheter ablation, during which time numerous ectopic firings and increased excitability throughout the right atrium were documented. Mutational analysis identified a novel missense mutation, M1875T, in <i>SCN5A</i> . Further investigations revealed the familial aggregation of this mutation in all of the affected individuals. Functional assays of the M1875T $\text{Na}^+$ channels using a whole-cell patch-clamp demonstrated a distinct gain-of-function type modulation; a pronounced depolarized shift (+16.4 mV) in $V_{1/2}$ of the voltage dependence of steady-state inactivation; and no persistent $\text{Na}^+$ current, which is a defining mechanism of LQTS3. These biophysical features of the mutant channels are potentially associated with increased atrial excitability and normal QT interval in all of the affected individuals.
<b>Conclusions</b>	We identified a novel <i>SCN5A</i> mutation associated with familial AF. The mutant channels displayed a gain-of-function type modulation of cardiac $\text{Na}^+$ channels, which is a novel mechanism predisposing to increased atrial excitability and familial AF. This is a new phenotype resulting from the <i>SCN5A</i> gain-of-function mutations and is distinct from LQTS3. (J Am Coll Cardiol 2008;52:1326–34) © 2008 by the American College of Cardiology Foundation

The cardiac sodium ( $\text{Na}^+$ ) channel plays a crucial role in cardiac excitation/contraction via initiating the action potential of the conduction system and working myocytes. Mutations in *SCN5A*—which encodes the  $\alpha$ -subunit of voltage-gated cardiac  $\text{Na}^+$  channels—have been associated with a variety of cardiac arrhythmias. The loss-of-function mutations result in Brugada syndrome (1), idiopathic ventricular fibrillation (2), cardiac conduction disease (3), or congenital sick sinus syndrome (4), whereas the gain-of-

function type modulation in *SCN5A* is associated with only 1 phenotype, long-QT syndrome type 3 (LQTS3) (5).

We reported on the screening for *SCN5A* mutations in Japanese patients with Brugada syndrome (6) and now have extended the cohort to various inherited arrhythmias, given the wide spectrum of clinical phenotypes of cardiac  $\text{Na}^+$  channelopathies. In the present study, in a Japanese family with lone atrial fibrillation (AF), we identified a novel missense mutation of *SCN5A* (M1875T). Until recently, only potassium channel mutations have been linked to familial AF (7–10); however, 3 recent reports have identified *SCN5A* loss-of-function mutations: D1275N in 2 families with atrial arrhythmias (AF, cardiac conduction disease, or sick sinus syndrome) plus dilated cardiomyopathy (11,12), and N1986K in a family with lone AF (13). Thus, this is the first report to identify an *SCN5A* gain-of-function type mutation in familial AF.

From the \*Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan; and the †Department of Cardiovascular and Respiratory Medicine, Shiga University of Medical Science, Otsu, Japan. This work was supported by research grants from the Japan Heart Foundation/Pfizer Japan Inc. Grant for Research on Cardiovascular Disease; Grants-in-Aid in Scientific Research from the Ministry of Education, Culture, Science, and Technology of Japan; and a Health Sciences Research Grant (H18-Research on human Genome-002) from the Ministry of Health, Labor and Welfare of Japan.

Manuscript received March 3, 2008; revised manuscript received July 7, 2008, accepted July 10, 2008.

**Methods**

**Clinical evaluation.** This study was approved by the Institutional Ethics Committee, and all patients provided informed consent. Affected individuals were considered as having AF or premature atrial contractions (PACs) when documented by 12-lead electrocardiograms (ECGs). Lone AF was defined as onset of AF at age <65 years without structural heart disease, hypertension, hyperthyroidism, myocardial infarction, or congestive heart failure. Paroxysmal AF was defined as sporadic AF lasting >30 s for <7 days. When sustained beyond 7 days, AF was considered persistent. Atrial fibrillation refractory to cardioversion or not attempted was classified as permanent. In both sinus rhythm and AF, the mean QT and RR intervals were measured from 3 and 6 consecutive beats, respectively.

**Deoxyribonucleic acid (DNA) isolation and mutation analysis.** Genomic DNA was isolated from blood lymphocytes and screened for candidate genes by denaturing high-performance liquid chromatography with a WAVE System Model 3500 (Transgenomic, Omaha, Nebraska). Abnormal conformers were amplified by polymerase chain reaction,


and sequencing was performed on an ABI PRISM 3100 DNA sequencer (Applied Biosystems, Foster City, California).

**Site-directed mutagenesis and electrophysiology.**

To construct the *SCN5A* mutant, we adopted site-directed mutagenesis performed via a kit, QuickChange II XL (Stratagene, La Jolla, California). The human cell line HEK293 cultured in a 35-mm dish was transiently transfected with 0.5 μg of either pRcCMV-WT or mutant complementary DNA in combination with 0.5 μg of the bicistronic plasmid (pEGFP-IRES-hβ1) encoding enhanced green fluorescent protein and the human β1-subunit (hβ1). The Na<sup>+</sup> currents were recorded 48 h after transfection with the whole-cell patch-clamp technique at 22°C to 23°C as described elsewhere (14). Results are expressed as mean ± SEM, and statistical significance was established with the Student *t* test. Statistical significance was assumed for *p* < 0.05.


**Abbreviations and Acronyms**

- AF = atrial fibrillation
- AT = atrial tachycardia
- ECG = electrocardiogram
- LQTS3 = long-QT syndrome type 3
- PAC = premature atrial contraction
- WT = wild-type



**Figure 1** Pedigree and Clinical Features

(A) Pedigree of the family. Phenotypic traits are designated within pedigree symbols. (B) Electrocardiograms (ECGs) obtained from the proband, IV-3, before (left panel, atrial fibrillation [AF]) and after (right panel, sinus rhythm) he underwent radiofrequency catheter ablation. (C) At rest and post-exercise ECGs recorded from the proband (IV-3) and his uncle (III-1). Exercise-induced AF for the proband and atrial tachycardia for the uncle can be observed. Continued on next page.



**Figure 1. Continued**

(D) Electrocardiograms recorded from other affected individuals. **Arrows** indicate P waves of premature atrial contractions (PACs) in II-3, III-1, and IV-1. III-3 and IV-4 demonstrated AF.

**Results**

**Clinical features.** We studied a Japanese family with autosomal dominant hereditary AF that spanned 3 generations (Fig. 1A). The proband (IV-3) (Fig. 1A), a 31-year-old man, first experienced repetitive palpitation due to frequent PACs at age 18, which later progressed to paroxysmal AF and atrial tachycardia (AT) at age 27 years (pre-ablation) (Fig. 1B).

Six family members, along with the proband, presented with either AF or frequent PACs (Fig. 1A). The majority shared a similar clinical course with the proband—palpitations due to PACs start in their teens, which later progress to paroxysmal and ultimately persistent AF (Table 1). The proband and his uncle (III-1) showed exercise-induced AT and/or AF (Fig. 1C). The proband’s cousin (IV-1) presented with frequent PACs (Fig. 1D) that have not yet progressed to AF. The ECGs of the affected relatives—with the exception to the proband’s aunt (II-3), who received

disopyramide—did not show any QT prolongation (Fig. 1D, Table 1). Interestingly, the analysis of P wave morphology in the affected family members revealed that the majority of PAC foci were localized in the right atrium (Fig. 1D). The affected individuals received various antiarrhythmic agents (Table 1) but, in most cases, to no avail. There was neither structural heart disease nor a history of major ventricular arrhythmias or sudden cardiac death in this family.

At age 27 years, the proband underwent radiofrequency catheter ablation. Intravenous administration of isoproterenol induced repetitive ATs from multiple origins in the right atrium (Fig. 2A). We successfully ablated the major origin, located in the lower-right atrial septum (Figs. 2B and 2C).


Three years later, the second ablation session was performed due to a relapse of persistent AF. This time, we identified 2 other PAC foci in the right atrium (Fig.

**Table 1. Clinical Characteristics of Affected Individuals**

Individual	Gender	Age (yrs)	Arrhythmias	Onset of PAC (yrs)	Onset of AF (yrs)	Mutation Carrier	HR (beats/min)	QRS (ms)	QTc	LAD (mm)	LVEF (%)	Antiarrhythmic Agents Used to Treat AF
I-2	F	90*	Unknown	NA	NA	ND	NA	NA	NA	NA	NA	NA
II-2	F	75*	Permanent AF	NA	NA	ND	88	74	427	36	79	—
II-3	F	75*	Paroxysmal AF, PACs	NA	NA	ND	77†	104†	478†	30	75	Disopyramide
III-1	M	60	Paroxysmal AF, PACs	NA	48	Yes	70	92	394	32	75	Disopyramide, cibenzoline, aprindine
III-3	M	57	Permanent AF	15	51	Yes	71	82	385	NA	NA	—
IV-1	M	34	PACs	23	—	Yes	68	82	399	ND	ND	—
IV-3	M	31	Persistent AF	18	27	Yes	65	81	388	30	63	Flisicalinide, flecainide
IV-4	F	29	Permanent AF	12	26	Yes	88	87	429	31	61	Flisicalinide


\*Age of death; †disopyramide administration.

AF = atrial fibrillation; HR = heart rate; LAD = left atrial dimension; LVEF = left ventricular ejection fraction; NA = records not available; ND = not determined; PAC = premature atrial contraction.



**Figure 2** Radiofrequency Catheter Ablation Recordings

The first (**A to C**) and the second (**D and E**) ablation sessions on the proband. (**A**) Repetitive atrial tachycardias (ATs) from multiple origins. Shown are intracardiac recordings from the coronary sinus (CS), the His bundle (His), and a catheter placed along the posterior septum (PS) in the right atrium. Note that atrial activation sequences in CS during ATs were consistently proximal to distal, suggesting right atrial origins. **Asterisks** indicate the successfully ablated AT originating from the lower-right atrial septum. (**B**) Fluoroscopic images of the electrodes in the left anterior oblique (LAO) and right anterior oblique (RAO) views. Position of the ablation catheter (ABL; indicated by **arrows**); successful ablation site of the AT. (**C**) Three-dimensional electroanatomic map of the AT in the right posterior oblique view. The AT focus in the lower-right atrial septum was successfully ablated in the first session. (**D**) Noncontact mapping of PACs in the right lateral view. Two PAC foci in the middle of the crista terminalis (**upper panel**) and the high posterolateral wall (**lower panel**) ablated successfully in the second session are shown. (**E**) Numerous electrical firings (**▲**) from the contact site during radiofrequency energy delivery in generating tricuspid valve isthmus block. Continuous pacing was performed from proximal CS. Stim = stimulator; TV = tricuspid valve annulus; other abbreviations as in Figure 1.



**Figure 3** Genetic Analysis

(A) The denaturing high-performance liquid chromatography elution profiles for an *SCN5A* mutation, M1875T, detected in the affected family members. (B) Deoxyribonucleic acid sequencing electropherograms demonstrate heterozygosity for a *SCN5A* mutation. (C) Topology of the  $\alpha$ -subunit of voltage-gated cardiac sodium ( $\text{Na}^+$ ) channel. The location of the detected mutation is shown. (D) Amino acid sequence alignments of *SCN5A* with related  $\text{Na}^+$  channels. The *SCN5A* indicates human heart; *SCN1A*, human brain type I; *SCN2A*, human brain type II; *SCN3A*, human brain type III; *SCN4A*, human skeletal muscle. The sequences of other species represent the cardiac isoforms of  $\text{Na}^+$  channels.


2D)—both were successfully ablated. During the subsequent procedure to generate a cavotricuspid isthmus block, we noticed that energy delivery from the catheter induced numerous electrical firings from the contact sites (Fig. 2E). After the second ablation session, he maintained a sinus rhythm under medication, yet even after which he experienced occasional episodes of paroxysmal AF. Interestingly, after each attempt of cardioversion, ATs that lasted for several seconds were observed immediately after the shock was delivered and before sinus rhythm conversion (data not shown). All of these features strongly suggest the proband's increased vulnerability to atrial arrhythmias.

**Genetic analysis.** We identified a novel missense mutation, c.5624T>C, p.M1875T, in the *SCN5A* gene in the proband. Figure 3 shows the denaturing high-performance liquid chromatography and sequence results (Figs. 3A and 3B) and an illustration showing the position of the identified mutation (Fig. 3C). The amino acid at codon 1875 (methionine) is highly conserved among different  $\text{Na}^+$  channel isoforms and species (Fig. 3D). Furthermore, this mutation was absent in 210 Japanese control individuals (420 chromosomes). We failed to identify mutations in any other potential candidate genes of familial AF (*KCNQ1*, *KCNH2*, *KCNE1*, *KCNE2*, *KCNE3*, *KCNJ2*, and *KCNA5*). Further analysis of the family members revealed that the M1875T mutation in *SCN5A*

perfectly matched their clinical phenotypes (Figs. 1A and 1D, Table 1).

**Functional analysis of M1875T-*SCN5A*.** We performed biophysical assays for the novel *SCN5A* mutation with a heterologous expression system in HEK293 cells. Figure 4A illustrates representative whole-cell current traces from cells expressing wild-type (WT) and M1875T  $\text{Na}^+$  channels in the presence of the coexpressed  $\text{Na}^+$  channel  $\beta$  subunit.

Notably, M1875T channels showed an apparently slower inactivation compared with WT. The time constants for both fast and slow inactivation across a wide range of test potentials were significantly larger with M1875T in comparison with WT (Fig. 4B), indicating impaired inactivation. Figure 4C shows the peak current-voltage relation for WT and M1875T channels. The maximum current density of WT was observed at  $-20$  mV but shifted to  $-30$  mV for M1875T. In addition, the peak current density of M1875T was significantly larger than WT (WT,  $326.2 \pm 28.2$  pA/pF,  $n = 23$ ; M1875T,  $484.6 \pm 49.6$  pA/pF,  $n = 31$ ,  $p < 0.01$ ) (Fig. 4D). As in WT, M1875T channels showed no persistent inward  $\text{Na}^+$  currents at the end of a 200-ms depolarization (Fig. 4E), which is one of the defining mechanisms of QT interval prolongation in patients with LQTS3. The subtracted amplitude at the end of the 200-ms depolarization was  $0.046 \pm 0.009\%$  ( $n = 5$ ) of the peak current for WT and  $0.048 \pm 0.038\%$  ( $n = 7$ ) for M1875T.



**Figure 4** Macroscopic Na<sup>+</sup> Currents of M1875T Channels

(A) Representative whole-cell current traces of wild-type (WT) and M1875T sodium (Na<sup>+</sup>) channels. Cells were transfected with human  $\beta 1$ -subunit (protocol shown as an inset). (B) Voltage dependence of inactivation time constants. The time course of inactivation was fit with a 2 exponential equation:  $I/I_{max} = A_f \times \exp(-t/\tau_f) + A_s \times \exp(-t/\tau_s)$ . Lower and upper bundles of symbols indicate fast ( $\tau_f$ ) and slow ( $\tau_s$ ) time constant values, respectively. Statistically significant differences are indicated (\* $p < 0.05$ , \*\* $p < 0.01$ ). (C) Average current-voltage relationship for WT and M1875T channels. The current is normalized to cell capacitance to give a measure of Na<sup>+</sup> current density. Asterisks indicate the voltages at which the current density was statistically different (\* $p < 0.05$ ). (D) Average peak Na<sup>+</sup> current density of WT and M1875T channels. The peak current density was significantly larger in M1875T (WT at  $-20$  mV,  $326.2 \pm 28.2$  pA/pF,  $n = 23$ ; M1875T at  $-30$  mV,  $484.6 \pm 49.6$  pA/pF,  $n = 31$ ,  $p < 0.05$ ). (E) Representative Na<sup>+</sup> current traces recorded in the absence or presence of  $30 \mu\text{mol/l}$  tetrodotoxin. Tetrodotoxin-sensitive persistent currents were calculated by digital subtraction. M1875T channels showed no persistent inward Na<sup>+</sup> currents.

Figure 5A shows the conductance-voltage and steady-state inactivation curves for WT and M1875T channels. Numerical data pertaining to the biophysical properties therein are summarized in Table 2. The parameters for the activation gate were similar between WT and M1875T. In contrast, the half-maximal potential ( $V_{1/2}$ ) for the steady-state inactivation of M1875T showed a marked positive shift (+16.4 mV) compared with that of WT (WT,  $V_{1/2} = -78.08 \pm 0.94$  mV,  $n = 22$ ; M1875T,  $V_{1/2} = -61.68 \pm 0.76$  mV,  $n = 33$ ,  $p < 0.01$ ). The slope factor ( $k$ ) for

M1875T was significantly larger than that of WT (WT,  $k = -7.13 \pm 0.12$ ,  $n = 22$ ; M1875T,  $k = -6.07 \pm 0.16$ ,  $n = 33$ ,  $p < 0.01$ ). The pronounced depolarizing shift of the inactivation gate is likely to increase Na<sup>+</sup> channel availability during excitation.

We also investigated the other kinetic properties of Na<sup>+</sup> channels: recovery from inactivation, onset of slow inactivation, and closed-state inactivation. Parameters of recovery from inactivation and onset of slow inactivation were identical between WT and M1875T (Figs. 5B and 5C,

**Table 2** Biophysical Properties of WT and M1875T Channels

	WT	M1875T
Activation (mV)	(n = 23)	(n = 37)
V <sub>1/2</sub>	-43.61 ± 0.79	-44.09 ± 0.72
k	6.53 ± 0.16	5.98 ± 0.18
Steady-state inactivation (mV)	(n = 22)	(n = 33)
V <sub>1/2</sub>	-78.08 ± 0.94	-61.68 ± 0.76†
k	-7.13 ± 0.12	-6.07 ± 0.16†
Recovery from inactivation	(n = 16)	(n = 25)
A <sub>r</sub>	0.84 ± 0.01	0.84 ± 0.01
A <sub>s</sub>	0.15 ± 0.01	0.15 ± 0.01
τ <sub>r</sub> (ms)	8.95 ± 0.95	8.32 ± 0.83
τ <sub>s</sub> (ms)	338.6 ± 30.4	271.6 ± 31.6
Onset of slow inactivation	(n = 15)	(n = 16)
A	0.12 ± 0.01	0.12 ± 0.01
τ (ms)	773.9 ± 90.0	647.2 ± 70.6
Closed-state inactivation	(n = 9)	(n = 9)
A	0.13 ± 0.03	0.05 ± 0.02*
τ (ms)	97.1 ± 7.8	212.7 ± 22.3†

Data are mean ± SEM. Parameters were obtained from fitting individual experiments illustrated in Figure 4. \*p < 0.05; †p < 0.01 versus wild-type (WT).

A and τ = fractional amplitude and time constant, respectively; n = number of tested cells; V<sub>1/2</sub> and k = midpoint potential and slope factor, respectively.

Table 2). With regard to closed-state inactivation, the extent was significantly less (WT, A = 0.13 ± 0.03 ms, n = 9; M1875T, A = 0.05 ± 0.02 ms, n = 9, p < 0.05), and the time constant was larger in the M1875T channels when compared with WT (WT, τ = 97.1 ± 7.8 ms, n = 9; M1875T, τ = 212.7 ± 22.3 ms, n = 9, p < 0.01) (Fig. 5D, Table 2). These data suggest that the number of inactivated M1875T channels is reduced near the resting potential.

Collectively, the M1875T mutation exhibited a gain-of-function type modulation in the cardiac Na<sup>+</sup> channels without persistent inward Na<sup>+</sup> currents: increased peak Na<sup>+</sup> channel density; prolonged time constants of both fast and slow inactivation; a large depolarizing shift in V<sub>1/2</sub> of the steady-state inactivation; and a lesser extent and a larger time constant with regard to closed-state inactivation. In short, the M1875T mutation clearly demonstrates characteristics that make it distinct from the LQTS3-type gain-of-function modulation.

## Discussion


In the present study, we identified a novel gain-of-function *SCN5A* mutation that causes a familial form of AF. The clinical course of AF development materialized in a similar fashion among all affected family members (i.e., palpitations due to frequent PACs and ATs in their teens, followed by paroxysmal and then persistent AF). During the clinical electrophysiological study in the proband, we recognized multifocal activity sites and increased excitability in the right atrium. These distinguishing features are presumably associated with the unique biophysical properties of the mutant Na<sup>+</sup> channels. It should be noted, however,

that the size of the pedigree analyzed in this study is limited.

**SCN5A mutations and familial AF.** Mutations in *SCN5A* have been reported to cause a wide variety of cardiac arrhythmias. The gain-of-function mutations result in LQTS3 (5), whereas the loss-of-function mutations result in various phenotypes: 1) Brugada syndrome; 2) idiopathic ventricular fibrillation; 3) cardiac conduction disease; and 4) congenital sick sinus syndrome. We previously reported that *SCN5A*-linked Brugada syndrome is a high-risk group of bradyarrhythmias, linked predominantly to sick sinus syndrome (6). Although AF is a common complication of Brugada syndrome (10% to 30%) (6,15), there is a scarcity of reports on *SCN5A*-positive Brugada syndrome and AF.

Atrial fibrillation is the most common form of cardiac arrhythmia, characterized by rapid irregular activation of the atrium, and a common cause of morbidity and mortality. Atrial fibrillation occurs predominantly in elderly persons and is frequently associated with underlying cardiac diseases. In 15% to 30% of patients, however, an etiology is absent (i.e., lone AF) (16,17). Although AF has been regarded a sporadic and acquired disease, the familial aggregation of AF has been shown to be more frequent than previously recognized (18,19). Chen et al. (7) found the first gene mutation responsible for familial AF in *KCNQ1*, which encodes the α-subunit of slow delayed rectifier potassium (K<sup>+</sup>) channels. Since then, 3 additional genes—all of which encode cardiac K<sup>+</sup> channels—responsible for familial AF have been identified: *KCNE2* (8), *KCNJ2* (9), and *KCNA5* (10). Recently, loss-of-function *SCN5A* mutations (D1275N) were reported to be associated with 2 families who have atrial arrhythmias (AF, cardiac conduction disease, and sick sinus syndrome) with dilated cardiomyopathy (11,12). More recently, an *SCN5A* mutation (N1986K) was identified in a family with lone AF (13). Functional assays on the N1986K channels revealed a hyperpolarized shift of steady-state inactivation, indicating a loss-of-function type modulation. One of the affected members underwent pacemaker implantation due to sick sinus syndrome, suggesting the underlying conduction disturbance resulting from the Na<sup>+</sup> channel loss-of-function. In addition, a common polymorphism (H558R) in *SCN5A*, present in 20% of the population (20), reduces Na<sup>+</sup> current density (21). The screening for the polymorphism in 157 patients with lone AF revealed that the R558 allele was more common in patients with lone AF than in the control subjects and as such was considered to be a risk factor for lone AF (22). However, none of the M1875T-positive individuals carried the R558 allele.

These reports implicate a potential relationship between decreased Na<sup>+</sup> currents and AF; however, to date, an *SCN5A* gain-of-function mutation has never been linked to AF.



**Figure 5** Gating Properties for M1875T Channels

Detailed parameters are given in Table 2. (A) Voltage dependence of relative sodium (Na<sup>+</sup>) conductance activation and steady-state inactivation were determined by means of the voltage protocols, as shown in the inset. Curves were fit with the Boltzmann equation,  $I/I_{max} = (1 + \exp[(V - V_{1/2})/k])^{-1}$  to determine the membrane potential for half-maximal inactivation or activation ( $V_{1/2}$ ) and the slope factor  $k$ . Note that M1875T channels showed a pronounced depolarized shift (+16.4 mV) in the  $V_{1/2}$  of steady-state inactivation compared with wild-type (WT). (B) Time course of recovery from inactivation was elicited with a double pulse protocol. Data were fit with a 2 exponential equation:  $I/I_{max} = A_f \times (1 - \exp[-t/\tau_f]) + A_s \times (1 - \exp[-t/\tau_s])$ , where  $A_f$  and  $A_s$  are fractions of fast and slow inactivation components, and  $\tau_f$  and  $\tau_s$  are the time constants of fast and slow inactivation components, respectively. (C) Onset of slow inactivation. Time course of entry into the slow inactivation state was obtained by a double pulse protocol. Curves were fit with a single exponential equation:  $I/I_{max} = y_0 + A \times \exp(-t/\tau)$ . (D) Closed-state inactivation. The transfer rate of Na<sup>+</sup> channels from closed-state to inactivated closed-state without an intervening opening state was measured by a double pulse protocol. Time course for development of closed-state inactivation was fit with a single exponential equation:  $I/I_{max} = y_0 + A \times \exp(-t/\tau)$ . The extent of closed-state inactivation was significantly less and the time constant larger in M1875T channels in comparison with WT.

**Unique gain-of-function properties of M1875T Na<sup>+</sup> channels.** To date, *SCN5A* gain-of-function mutations have been reportedly linked to only 1 phenotype, LQTS3. Persistent inward Na<sup>+</sup> currents observed in these mutant channels are considered to cause QT prolongation. However, M1875T channels did not display persistent inward Na<sup>+</sup> currents (Fig. 4E). This might explain why all of the affected and mutation-positive individuals in our study exhibited normal QT interval, with the exception of 1 individual who received disopyramide therapy. The functional properties of M1875T Na<sup>+</sup> channels were quite distinct from those of LQTS3. The most prominent change was a +16.4 mV shift in the steady-state inactivation. This is, to the best of our knowledge, the greatest depolarization shift in all of the previously reported *SCN5A* mutants. Some of the LQTS3 mutants (E1295K, A1330P, A1330T, and I1768V) showed a similar depolarizing shift of the steady-state inactivation without persistent inward Na<sup>+</sup>

currents; however, the extent of the depolarizing shift was much less than M1875T (all were < +10 mV). The M1875T channels displayed the increased peak Na<sup>+</sup> current density (Fig. 4D), perhaps due to the large depolarized shift in steady-state inactivation. Interestingly, the location of the mutation is within a complex region that includes Ca<sup>2+</sup> binding EF-hand like motifs and a putative binding site for calmodulin (23), and thus the mutation might disrupt inactivation by altered calcium sensitivity.

The potential mechanisms by which the identified gain-of-function mutation might lead to PAC or AF could be explained as the following: first, increased inward Na<sup>+</sup> currents might cause repolarization failure or early afterdepolarizations, thereby inducing triggered activities; and second, the increased Na<sup>+</sup> currents might increase the conduction velocity and facilitate the maintenance of the fibrillation wave. However, further studies are needed to elucidate the underlying mechanisms.



**Genotype–phenotype relationship and clinical implications.** Quite impressively, the affected family members shared a similar clinical course with high penetrance—frequent PACs and ATs first appeared during their teens and subsequently progressed to AF (Fig. 1A). Increased automaticity and irritability in the atrium was demonstrated by recurrent atrial arrhythmias that were resistant to ablation or drug therapy, induced PACs during exercise (Fig. 1C), and numerous ectopic firings and increased excitability throughout the right atrium during catheter ablation (Fig. 2). Because Na<sup>+</sup> channels encoded by *SCN5A* are expressed in both the atrium and ventricle, it remains unknown why our patients showed only atrial arrhythmias but not ventricular arrhythmias. The different electrophysiological properties between atrial and ventricular cells might be the underlying cause. Resting membrane potential is more depolarized, and the peak Na<sup>+</sup> current density is larger in atrial cells than in ventricular cells in dogs (24). The critical depolarization and current threshold for action potential initiation are smaller in atrial cells than in ventricular cells, indicating that atrial cells are more readily excitable than ventricular cells (25).

## Conclusions

We identified a novel *SCN5A* gain-of-function mutation that causes a familial form of AF without any underlying structural heart diseases, which provides us with new insight into the pathogenesis of the commonly occurring form of AF.

## Acknowledgment

The authors thank Richard Kaszynski for his critical reading of the manuscript.

**Reprint requests and correspondence:** Dr. Masaharu Akao, Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan. E-mail: akao@kuhp.kyoto-u.ac.jp.

## REFERENCES

1. Chen Q, Kirsch GE, Zhang D, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. *Nature* 1998;392:293–6.
2. Akai J, Makita N, Sakurada H, et al. A novel *SCN5A* mutation associated with idiopathic ventricular fibrillation without typical ECG findings of Brugada syndrome. *FEBS Lett* 2000;479:29–34.
3. Schott JJ, Alshinawi C, Kyndt F, et al. Cardiac conduction defects associate with mutations in *SCN5A*. *Nat Genet* 1999;23:20–1.
4. Benson DW, Wang DW, Dymant M, et al. Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (*SCN5A*). *J Clin Invest* 2003;112:1019–28.
5. Wang Q, Shen J, Splawski I, et al. *SCN5A* mutations associated with an inherited cardiac arrhythmia, long QT syndrome. *Cell* 1995;80:805–11.
6. Makiyama T, Akao M, Tsuji K, et al. High risk for bradyarrhythmic complications in patients with Brugada syndrome caused by *SCN5A* gene mutations. *J Am Coll Cardiol* 2005;46:2100–6.
7. Chen YH, Xu SJ, Bendahhou S, et al. *KCNQ1* gain-of-function mutation in familial atrial fibrillation. *Science* 2003;299:251–4.
8. Yang Y, Xia M, Jin Q, et al. Identification of a *KCNE2* gain-of-function mutation in patients with familial atrial fibrillation. *Am J Hum Genet* 2004;75:899–905.
9. Xia M, Jin Q, Bendahhou S, et al. A *Kir2.1* gain-of-function mutation underlies familial atrial fibrillation. *Biochem Biophys Res Commun* 2005;332:1012–9.
10. Olson TM, Alekseev AE, Liu XK, et al. *Kv1.5* channelopathy due to *KCNA5* loss-of-function mutation causes human atrial fibrillation. *Hum Mol Genet* 2006;15:2185–91.
11. McNair WP, Ku L, Taylor MRG, et al. *SCN5A* mutation associated with dilated cardiomyopathy, conduction disorder, and arrhythmia. *Circulation* 2004;110:2163–7.
12. Olson TM, Michels VV, Ballew JD, et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. *JAMA* 2005;293:447–54.
13. Ellinor PT, Nam EG, Shea MA, Milan DJ, Ruskin JN, Macrae CA. Cardiac sodium channel mutation in atrial fibrillation. *Heart Rhythm* 2008;5:99–105.
14. Shirai N, Makita N, Sasaki K, et al. A mutant cardiac sodium channel with multiple biophysical defects associated with overlapping clinical features of Brugada syndrome and cardiac conduction disease. *Cardiovasc Res* 2002;53:348–54.
15. Bordachar P, Reuter S, Garrigue S, et al. Incidence, clinical implications and prognosis of atrial arrhythmias in brugada syndrome. *Eur Heart J* 2004;25:879–84.
16. Murgatroyd FD, Camm AJ. Atrial arrhythmias. *Lancet* 1993;341:1317–22.
17. Levy S, Maarek M, Coumel P, et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. *Circulation* 1999;99:3028–35.
18. Darbar D, Herron KJ, Ballew JD, et al. Familial atrial fibrillation is a genetically heterogeneous disorder. *J Am Coll Cardiol* 2003;41:2185–92.
19. Ellinor PT, Yoerger DM, Ruskin JN, MacRae CA. Familial aggregation in lone atrial fibrillation. *Hum Genet* 2005;118:179–84.
20. Ackerman MJ, Splawski I, Makielski JC, et al. Spectrum and prevalence of cardiac sodium channel variants among black, white, Asian, and Hispanic individuals: implications for arrhythmogenic susceptibility and Brugada/long QT syndrome genetic testing. *Heart Rhythm* 2004;1:600–7.
21. Makielski JC, Ye B, Valdivia CR, et al. A ubiquitous splice variant and a common polymorphism affect heterologous expression of recombinant human *SCN5A* heart sodium channels. *Circ Res* 2003;93:821–8.
22. Chen LY, Ballew JD, Herron KJ, Rodeheffer RJ, Olson TM. A common polymorphism in *SCN5A* is associated with lone atrial fibrillation. *Clin Pharmacol Ther* 2007;81:35–41.
23. Deschenes I, Neyroud N, DiSilvestre D, Marban E, Yue DT, Tomaselli GF. Isoform-specific modulation of voltage-gated Na(+) channels by calmodulin. *Circ Res* 2002;90:E49–57.
24. Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. *Circulation* 2007;116:1449–57.
25. Golod DA, Kumar R, Joyner RW. Determinants of action potential initiation in isolated rabbit atrial and ventricular myocytes. *Am J Physiol Heart Circ Physiol* 1998;274:H1902–13.

**Key Words:** arrhythmia ■ atrial fibrillation ■ genetics ■ ion channels ■ sodium.

# Better Survival With Statin Administration After Revascularization Therapy in Japanese Patients With Coronary Artery Disease

## — Perspectives From the CREDO-Kyoto Registry —

Yutaka Furukawa, MD; Ryoji Taniguchi, MD\*; Natsuhiko Ehara, MD; Neiko Ozasa, MD\*\*;  
Yoshisumi Haruna, MD†; Naritatsu Saito, MD\*\*; Takahiro Doi, MD\*\*; Kozo Hoshino, MD††;  
Satoshi Shizuta, MD\*\*; Takeshi Morimoto, MD‡; Yukiko Imai, MPH‡‡;  
Satoshi Teramukai, PhD‡‡; Masanori Fukushima, MD‡‡; Toru Kita, MD\*\*;  
Takeshi Kimura, MD\*\*; CREDO-Kyoto Investigators

**Background** The importance of statins in cardiovascular prevention has been demonstrated in various patient subsets. This study aimed to evaluate the effects of statins on long-term outcomes of Japanese patients undergoing their first coronary revascularization.

**Methods and Results** A total of 9,225 patients undergoing their first coronary revascularizations during 2000–2002 were divided into 2 groups according to the use of statins at discharge; patients with acute myocardial infarction were not included. Statins was administered to only 28.5% (n=2,630) of the patients. The median follow-up period was 3.5 years. Patients on statin therapy showed lower all-cause (5.2% vs 10.0%;  $p<0.0001$ ) and cardiovascular (3.2% vs 6.2%;  $p<0.0001$ ) mortality than those without statins (n=6,595) by Kaplan-Meier analysis and log-rank test. After adjustment by multivariate analysis according to 29 variables, statin therapy remained as an independent predictor of reduced all-cause (relative risk ratio (RR) 0.71, 95% confidence interval (CI) 0.59–0.86,  $p=0.0005$ ) and cardiovascular (RR 0.72, 95% CI 0.56–0.91,  $p=0.0067$ ) mortality. The validity of RR of statin therapy in multivariate analysis was further confirmed by risk adjustment using propensity scores (all-cause mortality: propensity-adjusted RR 0.70, 95% CI 0.58–0.85,  $p=0.0003$ ; cardiovascular mortality: propensity-adjusted RR 0.70, 95% CI 0.54–0.89,  $p=0.0038$ ).

**Conclusions** Statin therapy started at hospital discharge was associated with increased chance of survival in Japanese patients undergoing their first coronary revascularization. (Circ J 2008; 72: 1937–1945)

**Key Words:** Coronary artery disease; Mortality; Revascularization; Statins

Optimized medical therapy, as well as appropriate lifestyle modification, is important to reduce cardiovascular risks in the secondary prevention of coronary artery disease (CAD). Common medications for cardiovascular prevention in contemporary clinical practice include antiplatelet drugs, HMG-CoA reductase inhibitors

(statins), inhibitors of the rennin–angiotensin system (ie, angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II type I receptor blockers (ARB)), and  $\beta$ -adrenergic blockers.<sup>1,2</sup> In particular, consistent prognostic benefits of statins have been shown in a number of primary as well as secondary prevention trials.<sup>3–8</sup> The study subjects have been widely distributed from hypercholesterolemic patients without CAD to specific high-risk groups such as diabetic patients, patients with acute coronary syndrome and patients undergoing percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG).<sup>9–13</sup> Cardiovascular events can be further prevented when the low-density lipoprotein-cholesterol level is intensively decreased below the normal range with statin therapy.<sup>11,14</sup> Much of this evidence has been obtained from randomized trials in the United States or Europe where the prevalence and mortality of CAD are higher and higher doses of statins are approved by public medical insurance systems, relative to Japan. Therefore, the data may not be directly applicable to practice in different clinical and genetic backgrounds such as Japanese patients. Recently, coronary risk reduction by pravastatin has been shown in Japanese patients in the setting of primary prevention.<sup>15</sup> In addition, recent trials have demonstrated effective cardiovascular prevention by

(Received March 19, 2008; revised manuscript received July 7, 2008; accepted July 24, 2008; released online October 24, 2008)

Division of Cardiology, Kobe City Medical Center General Hospital, Kobe. \*Division of Cardiology, Hyogo Prefectural Amagasaki Hospital, Amagasaki. \*\*Department of Cardiovascular Medicine, Kyoto University Hospital, Kyoto. †Division of Cardiology, Department of Medicine, Hirakata Kohsai Hospital, Hirakata. ‡Division of Cardiology, Nagai Hospital, Tsu. ‡Center for Medical Education, Kyoto University Graduate School of Medicine, Kyoto and ‡‡Translational Research Informatics Center, Kobe, Japan

Investigators in the Coronary REvascularization Demonstrating Outcome study in Kyoto (CREDO-Kyoto) registry are listed in Appendix 1.

Mailing address: Yutaka Furukawa, MD, Division of Cardiology, Kobe City Medical Center General Hospital, 4-6 Minatogima-nakamachi, Chuo-ku, Kobe 650-0046, Japan. E-mail: furukawa@kegh.gr.jp

All rights are reserved to the Japanese Circulation Society. For permissions, please e-mail: cj@j-circ.or.jp

**Table 1** Baseline Characteristics of the Patients According to Statin Treatment at Hospital Discharge

Characteristic	Statin-treated (n=2,630)	Statin-non-treated (n=6,595)	p value
<i>Demographic characteristics</i>			
Age (mean±SD)	65.2±10.0	67.8±9.9	<0.0001
≥75 years (%)	18.1	26.4	<0.0001
Male gender (%)	62.6	73.7	<0.0001
Mode of revascularization PCI (%)	79.8	66.3	<0.0001
BMI (kg/m <sup>2</sup> )	24.4±3.2	23.4±3.2	<0.0001
≥25 kg/m <sup>2</sup> (%)	39.4	27.8	<0.0001
Family history of CAD (%)	19.1	14.4	<0.0001
Current smoking (%)	27.9	28.5	NS
<i>Coexisting conditions</i>			
Unstable angina (%)	7.7	7.5	NS
Prior MI (%)	22.6	26.5	0.0001
History of CHF (%)	11.8	18.4	<0.0001
History of CVA (%)	13.6	17.4	<0.0001
Peripheral vascular disease (%)	6.5	7.6	NS
Atrial fibrillation (%)	4.8	7.5	<0.0001
Anemia: Hb <10 g/dl (%)	3.9	7.8	<0.0001
COPD (%)	1.2	2.9	<0.0001
Liver cirrhosis (%)	1.6	3.7	<0.0001
Serum TC	211.9±44.4	193.1±35.3	<0.0001
≥220 mg/dl (%)	39.5	21.0	<0.0001
Serum LDL-C	130.1±41.1	119.0±31.2	<0.0001
≥130 mg/dl (%)	46.6	34.2	<0.0001
Serum HDL-C	50.2±14.8	47.3±13.5	<0.0001
<40 mg/dl (male); <50 mg/dl (female) (%)	32.8	37.8	<0.0001
Serum TG	163.6±103.3	137.2±84.2	<0.0001
≥150 mg/dl (%)	46.2	30.9	<0.0001
Hypertension (%)	71.3	68.4	0.0059
Diabetes mellitus (%)	40.6	38.0	0.0235
Insulin Tx (%)*	19.5	22.5	0.0495
CKD: GFR <60 ml/min (%)	31.8	42.9	<0.0001
Left main CAD (%)	7.3	10.3	<0.0001
Proximal LAD lesion (%)	41.1	42.6	NS
Multivessel disease (%)	63.6	63.6	NS

\*Values are presented as frequencies (%) within diabetic patients.

PCI, percutaneous coronary intervention; BMI, body mass index; CAD, coronary artery disease; NS, not statistically significant; MI, myocardial infarction; CHF, congestive heart failure; CVA, cerebrovascular accident; Hb, hemoglobin; COPD, chronic obstructive pulmonary disease; TC, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TG, triglycerides; Tx, therapy; CKD, chronic kidney disease; GFR, glomerular filtration rate; LAD, left anterior descending.

statin therapy in Japanese patients with acute myocardial infarction (AMI).<sup>16,17</sup> The association of statin therapy with better outcomes has also been shown in Japanese patients with AMI or angiographically proven CAD.<sup>18,19</sup>

The aim of this study was to assess the preventive effects of medical therapies prescribed at hospital discharge on the long-term prognosis in Japanese CAD patients undergoing their first coronary revascularization by PCI or CABG, with an emphasis on statins. The patients have been registered from 30 institutions cooperating in the Coronary REvascularization Demonstrating Outcome study in Kyoto (CREDO-Kyoto) registry.

## Methods

This study was approved by the institutional review boards or ethics committees of all participating institutions. Because the study subjects were retrospectively enrolled, written informed consent was not obtained, in concordance with the guidelines for epidemiologic studies issued by the Ministry of Health, Labor and Welfare of Japan. However, 73 patients were excluded because of their refusal to participate in the study when contacted for follow-up.

## CREDO-Kyoto Registry and the Study Subjects

Consecutive patients who underwent their first coronary revascularization during 2000–2002 have been enrolled in the CREDO-Kyoto registry. Patients with AMI within 1 week after onset have not been included. Thirty institutions (Appendix 1) participated in the multicenter registry, and the baseline and follow up data for 9,877 patients have been obtained.<sup>20</sup> After excluding patients with malignant diseases (n=496), those who died in hospital (n=62) and those without precise information about their medical treatment at discharge or follow-up data (n=94), 9,225 patients were subjected to the analyses.

## Data Collection, Definition and Follow-up

Clinical and analytical information of the study patients were collected from hospital charts or databases in each center by independent clinical research coordinators (Appendix 2) according to predetermined definitions. The baseline information of the patients included age, sex, smoking habit, body mass index (BMI), mode of revascularization, biochemistry before revascularization procedure, and comorbidities and background conditions such as hypertension, diabetes mellitus (DM), chronic kidney disease (CKD), anemia, peripheral vascular disease, history of heart failure, prior myocardial infarction (MI) or cerebrovascular acci-

**Table 2 Medications at Hospital Discharge**

Medication	All patients (n=9,225)	Statin-treated (n=2,630)	Statin-non-treated (n=6,595)	p value
Statins (%)	28.5	100	0	<0.0001
ACEI or ARB (%)	32.9	38.9	30.6	<0.0001
ACEI (%)	20.4	24.5	18.7	<0.0001
ARB (%)	13.4	15.6	12.5	<0.0001
$\beta$ -adrenergic blocker (%)	16.6	22.6	14.2	<0.0001
Calcium-channel blockers (%)	59.4	60.2	59.0	NS
Nitrates (%)	62.3	63.2	61.9	NS
Antiplatelet medications (%)	96.3	97.3	95.9	0.0014
Aspirin (%)	88.3	89.4	87.9	0.0382
Ticlopidine (%)	56.5	62.6	54.0	<0.0001

ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker. Other abbreviation see in Table 1.

dent. CKD was regarded as present when the glomerular filtration rate estimated by Cockcroft-Gould formula was <60 ml/min. Anemia was defined as blood hemoglobin level <10 g/dl. Peripheral vascular disease was as present when carotid, aortic and/or other peripheral vascular disease was being treated or was scheduled for surgical or endovascular interventions. Angiographic data of CAD, as well as precise information of the medical treatment at hospital discharge, were also obtained. The patients were followed up with respect to mortality for a median of 3.5 years. An independent clinical events committee adjudicated the events. All deaths were confirmed by medical records or telephone interview of the patients' families, and death was regarded as cardiovascular in origin unless obvious noncardiovascular causes could be identified. MI was adjudicated according to the definition in the Arterial Revascularization Therapy Study.<sup>21</sup> Within 1 week of the index procedure, only Q-wave MI was adjudicated as MI. Stroke during follow-up was defined as symptomatic stroke.

#### Statistical Analysis

All continuous variables are expressed as means  $\pm$  SD. Statistical significance of differences in subject baseline demographics between the patients with statin therapy and the patients without statin therapy at hospital discharge were assessed by a Student t-test for parametrically distributed continuous variables, the Wilcoxon signed-ranks test for nonparametrically distributed continuous variables or a Pearson's  $\chi^2$  test for categorized data analyses.

Following the descriptive statistics, we used Kaplan–Meier estimates to plot the percentage of patients in each group free from any death, cardiovascular death, MI, stroke or any revascularization procedure. The log-rank test was used to identify significant differences in unadjusted survival rates. To determine the significant and independent prognostic factors for mortality, we listed 22 potential baseline variables: mode of revascularization, old-old age ( $\geq 75$  years), male gender, BMI ( $\geq 25$  kg/m<sup>2</sup>), current smoking, hypertension, DM, peripheral vascular disease, cerebrovascular disease, atrial fibrillation, chronic obstructive pulmonary disease, CKD, liver cirrhosis, anemia, unstable angina, prior MI, history of congestive heart failure, high serum total cholesterol (TC  $\geq 220$  mg/dl) or triglycerides ( $\geq 150$  mg/dl) level, left main coronary artery (LMCA) disease, proximal left anterior descending artery lesion and multivessel disease, and 7 potential risk-reducing pharmacotherapies at hospital discharge: statins, ACEI, ARB,  $\beta$ -adrenergic blockers, antiplatelet drugs, nitrates and calcium-channel blockers. Thus, all continuous variables were dichotomized for fitting pro-




Fig 1. Kaplan–Meier analysis of cumulative rates of survival in coronary artery disease patients undergoing their first revascularization with vs without statin therapy at hospital discharge for all-cause (A) and cardiovascular (B) mortality.

portional assumption according to the predetermined clinical contexts. The relationships between the 29 variables and each of the endpoints were assessed using a multivariate Cox proportional hazards model with stepwise procedure. Variable selection was carried out, stepping up with  $p < 0.05$  as the requirement for inclusion and stepping down by deleting the term with the highest p-value until all remaining terms were significant with p-values  $< 0.05$ . In the multivariate analyses assessing the relationships between the 29 variables and MI, stroke and revascularization as the end-

**Table 3 Multivariate Analysis for Prognostic Factors of All-Cause Mortality**

Parameter	RR	95%CI	p value
Antiplatelet drugs at discharge	0.61	0.46–0.80	0.0003
BMI $\geq 25$ kg/m <sup>2</sup>	0.69	0.57–0.84	0.0002
Statins at discharge	0.71	0.59–0.86	0.0005
Nitrates at discharge	0.86	0.74–1.00	0.0446
CVA	1.25	1.06–1.47	0.0075
Diabetes mellitus	1.28	1.11–1.48	0.0009
Male gender	1.32	1.12–1.55	0.0007
Revascularization by PCI	1.35	1.14–1.59	0.0004
Multivessel disease	1.40	1.19–1.66	<0.0001
Liver cirrhosis	1.65	1.21–2.23	0.0014
COPD	1.68	1.23–2.29	0.0010
Peripheral vascular disease	1.70	1.38–2.08	<0.0001
Age $\geq 75$ years	1.93	1.65–2.25	<0.0001
History of heart failure	2.10	1.80–2.45	<0.0001
CKD	2.12	1.78–2.52	<0.0001
Hb <10 g/dl	2.28	1.89–2.74	<0.0001

RR, relative risk ratio; CI, confidence interval. Other abbreviations see in Table 1.

**Table 4 Multivariate Analysis for Prognostic Factors of Cardiovascular Mortality**

Parameter	RR	95%CI	p value
Antiplatelet drugs at discharge	0.63	0.45–0.90	0.0102
Statins at discharge	0.72	0.56–0.91	0.0067
BMI $\geq 25$ kg/m <sup>2</sup>	0.76	0.60–0.98	0.0335
Male gender	1.26	1.03–1.54	0.0220
Revascularization by PCI	1.29	1.06–1.58	0.0118
Diabetes mellitus	1.30	1.08–1.56	0.0064
CVA	1.37	1.12–1.68	0.0026
Multivessel disease	1.51	1.21–1.88	0.0003
Age $\geq 75$ years	1.62	1.33–2.00	<0.0001
Peripheral vascular disease	1.67	1.28–2.16	0.0001
History of heart failure	2.35	1.94–2.86	<0.0001
Hb <10 g/dl	2.42	1.93–3.03	<0.0001
CKD	2.94	2.32–3.71	<0.0001

Abbreviations see in Tables 1,3.

points, statin therapy was included in the variables, irrespective of its significance and independence as a prognostic predictor.

To evaluate the consistency of the association of statin therapy with reduced all-cause and cardiovascular mortality, multivariate analyses using the Cox proportional hazards models were also performed in predetermined subgroups. These included patients  $\geq 75$  years/ $<75$  years, male/female, PCI/CABG, diabetic/non-diabetic, hypertensive/non-hypertensive patients, and patients with/without high serum TC, high serum triglyceride, CKD, history of heart failure or prior MI. The same factors used for analysis of the total cohort were incorporated in the multivariate models for subgroup analyses. Interaction analyses were also carried out between each categorized subgroup.

Because standard adjustment measures were not always valid, because of suboptimal assessment of degree of overlapping baseline characteristics, propensity score analysis was also performed as described and implemented by Rubin and others, using the baseline characteristics as potential prognostic factors.<sup>22–24</sup> Essentially, this involves calculation of a propensity score, which is the probability that any given individual patient would be part of the statin-treated group as opposed to the statin-non-treated group. The prognostic factors to calculate the propensity score were the same 29 factors included as variables of the multivariate analyses.

All analyses were performed using SAS Ver 9.1.3 (SAS

Institute Inc, Cary, NC, USA) and all reported p-values are 2-sided.

## Results

### Subject Demographics and Characteristics of Medical Therapy at Discharge

A total of 9,225 study patients were divided into 2 groups based on the use of statin therapy at hospital discharge: 28.5% (n=2,630) of the subjects were on statin therapy and 71.5% (n=6,595) were not. Because of the large number of study patients and the observational study design, statistically significant differences were observed in many variables at baseline between the 2 groups. Significantly different variables include demographic characteristics such as the proportion of patients  $\geq 75$  years, male gender and mode of revascularization, comorbidities such as history of heart failure, other atherosclerotic diseases, dyslipidemia, diabetes and CKD, and the existence of LMCA disease (Table 1).

Prescription rates for ACEI, ARB, ACEI/ARB and  $\beta$ -adrenergic blockers at discharge were 20.4%, 13.4%, 32.9% and 16.6%, respectively. Most patients (96.3%) were treated with antiplatelet medications. Nitrates (62.3%) and calcium-channel blockers (59.4%) were prescribed in a considerably high proportion of the subjects (Table 2).

**Table 5 RR of Statin Therapy for All-Cause and Cardiovascular Mortality by Propensity Score Analysis Compared With Multivariate Analysis**

Endpoints and analysis	RR	95%CI	p value
<i>All-cause mortality</i>			
Multivariate analysis	0.71	0.59–0.86	0.0005
<i>Adjustment by propensity score analysis</i>			
Quintiles category	0.70	0.58–0.85	0.0003
Propensity score	0.73	0.61–0.89	<0.0001
Stratification of quintiles category	0.70	0.58–0.85	0.0003
<i>Cardiovascular mortality</i>			
Multivariate analysis	0.72	0.56–0.91	0.0067
<i>Adjustment by propensity score analysis</i>			
Quintiles category	0.70	0.54–0.89	0.0038
Propensity score	0.73	0.57–0.93	0.0102
Stratification of quintiles category	0.69	0.54–0.89	0.0036

Abbreviations see in Table 3.




Fig 2. Relative risk ratio (RR) and 95% confidence interval (CI) for all-cause mortality for patients with vs without statin therapy in various patient subgroups. CABG, coronary artery bypass graft surgery; PCI, percutaneous coronary intervention.

*Association of Statin Therapy With Unadjusted Survival*

During the follow-up (median=3.5 years) with 96% follow-up rate at ≥2 years, 136 deaths (5.2%) and 660 deaths (10.0%) occurred in the statin-treated and the statin-non-treated groups, respectively. Among them, 83 deaths (3.2%)

in the statin-treated and 405 deaths (6.2%) in the statin-non-treated groups were from cardiovascular events. Kaplan–Meier survival method and log-rank analysis in the 2 groups indicated that the unadjusted chance of survival free from all-cause, as well as cardiovascular, deaths was significant-




Fig 3. Relative risk ratio (RR) and 95% confidence interval (CI) for cardiovascular mortality for patients with vs without statin therapy in various patient subgroups. CABG, coronary artery bypass graft surgery; PCI, percutaneous coronary intervention.

ly greater in the statin-treated group ( $p < 0.0001$ , Fig 1).

*Association of Statin Therapy With Adjusted Survival*

The results of the multivariate analysis of the predictors of all-cause mortality using stepwise procedure are shown in Table 3, where the relative risk ratio (RR), 95% confidence interval (CI) and p-value of each factor are given. Statin therapy at discharge remained an independent predictor of an increased chance of survival (RR 0.71, 95% CI 0.59–0.86,  $p = 0.0005$ ). Antiplatelets (RR 0.61, 95% CI 0.46–0.80,  $p = 0.0003$ ) and higher BMI (RR 0.69, 95% CI 0.57–0.84,  $p = 0.0002$ ) were also included as independent factors predicting increased chance of survival. Nitrates might marginally contribute to the survival of patients.

Table 4 shows the results of the multivariate analysis of predictors of cardiovascular mortality. Similar to the results of the analysis of all-cause mortality, statin therapy at discharge was an independent predictor of survival free from cardiovascular death.

The RR of statin therapy for all-cause (RR 0.70, 95% CI 0.58–0.85,  $p = 0.0003$ ) or cardiovascular (RR 0.70, 95% CI

0.54–0.89,  $p = 0.0038$ ) mortality adjusted by quintiles category of propensity score was quite similar to the result of multivariate analysis (Table 5). In the sensitivity analysis, the RR of statin therapy adjusted by propensity score as a numeric variable and the RR of statin therapy adjusted by stratification of quintiles category of propensity score also showed similar results (Table 5). Thus, the validity of the RR of statin therapy for all-cause or cardiovascular mortality in the multivariate analysis was confirmed by risk adjustment using propensity scores.

*Consistency of Better Survival in Patients With Statin Therapy*

Subgroup analyses indicated consistently lower all-cause, as well as cardiovascular, mortality in patients with statin therapy in all subgroups (Figs 2,3). Point-estimate of the relative risk was less than 1.0 in all subgroups and no significant interaction was found between the subgroups in each category. The relative risk for all-cause mortality was statistically significantly lower in the statin-treated group than in the statin-non-treated group in patients at ages <75 years and

≥75 years, patients treated by PCI, male patients, both diabetic/non-diabetic patients, hypertensive patients, patients with serum TC <220mg/dl or serum triglyceride <150mg/dl, patients with/without CKD, patients with/without heart failure, and patients without prior MI (Fig 2). The significant association of statin therapy and the lower risk for cardiovascular mortality was also seen in various subgroups (Fig 3). Despite the consistency of the association of statin therapy and better outcomes, statins were used significantly less frequently in subgroups at higher cardiovascular risk such as male patients (25.3% on statins), older patients (21.5%), patients with CKD (22.9%), patients with a history of heart failure (20.3%) or a prior MI (25.4%). Post-CABG patients were significantly less frequently prescribed statins at hospital discharge (19.3%) than post-PCI patients (32.4%).

#### *Association of Statin Therapy With Future MI, Stroke and Coronary Revascularization*

Although crude survival free from stroke was significantly better in patients with statins, by Kaplan–Meier analysis and by log-rank test ( $p=0.0013$ ), statin therapy did not remain as an independent prognostic factor of stroke (444 total events: 99 in the statin-treated group, 345 in the statin-non-treated group; RR 0.83, 95% CI 0.66–1.04,  $p=0.0999$ ) after adjustment by multivariate analysis. With regard to MI (257 total events: 69 in the statin-treated group, 188 in the statin-non-treated group; RR 0.89, 95% CI 0.67–1.17,  $p=0.4019$ ) and any revascularization (2,835 total events: 876 in the statin-treated group, 1959 in the statin-non-treated group; RR 0.96, 95% CI 0.88–1.04,  $p=0.2768$ ), both crude survival and the results of the multivariate analyses failed to prove the significant association of statin therapy with better outcomes.

## Discussion

In the present study, we have shown that statin therapy at hospital discharge is associated with better outcomes in Japanese patients after their first coronary revascularization. All-cause, as well as cardiovascular, mortality was significantly lower in patients with statin therapy than in those without statins, after adjustments for coexisting coronary risk factors, mode of revascularization and concomitant medical treatments. The association of statin therapy with better survival was consistently shown among various patient subgroups.

#### *Characteristics of the Clinical Background of the Study Patients*

Our study patients consisted of a secondary prevention cohort with established CAD undergoing their first PCI or CABG. Approximately 70% of the patients underwent PCI and comprised a unique group at high risk of cardiovascular events associated with stent deployment, such as stent thrombosis and restenosis, and hemorrhagic complications related to dual antiplatelet drug therapy. Moreover, the subjects' baseline characteristics indicated a high prevalence of multiple coronary risk factors, suggesting the need for intensive risk factor management. Although racial differences in susceptibility to CAD might exist and previous observational studies have shown a lower prevalence of CAD in Japan relative to the United States<sup>25,26</sup> the all-cause mortality of the present patients without statins (10% at 3.5 years of median follow-up) appeared comparable with that of the

control group in the 4S study (12% at 5.4 years of median follow-up), a secondary prevention study in patients with stable CAD in Europe<sup>3</sup>. Thus, the present study has been performed in a unique Asian patient group at a mortality risk as high as a Caucasian secondary prevention cohort.

#### *Better Survival in Patients With Statin Therapy and its Consistency*

All-cause, as well as cardiovascular, mortality was significantly lower in Japanese patients with statin therapy who underwent their first coronary revascularization by PCI with bare-metal stent or by CABG. The findings are consistent with a previous small randomized trial<sup>12</sup> and an observational study that was carried out in Europe in patients after PCI.<sup>27</sup> Subgroup analysis revealed a survival advantage in patients with statin therapy in various high-risk subgroups such as older patients and patients with CKD. Analysis in patients with TC ≥220mg/dl did not indicate a significant difference in all-cause or cardiovascular mortality between the statin-treated and the non-treated groups. This unexpected result might be related to the smaller number of patients in the group with TC ≥220mg/dl (26.4% of all subjects). Indeed, there was a trend to favor statin therapy in regard to relative risk for all-cause or cardiovascular mortality, and the RR of the statin-treated group for cardiovascular mortality was comparable between patients with TC ≥220mg/dl and those with TC <220mg/dl. Thus, the results added further evidence to the consistent benefits of statins for secondary cardiovascular prevention. Because an admission for a coronary revascularization procedure is a good opportunity to optimize medical therapy for CAD, most patients undergoing PCI or CABG should be considered for the indication of statins.<sup>28</sup>

The multivariate analyses failed to show significant differences in the prevalence of MI, stroke and any coronary revascularization between the statin-treated and non-treated groups, although the relative risk appeared to favor statin therapy in the analyses for MI and stroke. Because the majority of the repeated revascularization procedures were performed within 1 year of the first revascularization, because of restenosis after stenting, the preventive role statins for restenosis appears deniable. In regard to MI and stroke, the prevalence might not be sufficiently high to show differences (2.8% for MI and 4.8% for stroke). In particular, longer follow-up or analysis in a larger patient population could increase the number of events and show a significant differences between the statin-treated and the non-treated groups in the prevalence of stroke, because a clear tendency of fewer strokes in the statin-treated group was observed. Another possible explanation may be the effect of statins on the severity of MI and stroke. It has been reported that pretreatment with statins decreases myocardial injury or periprocedural mortality during PCI or CABG.<sup>29–31</sup> Fonarow et al have shown in a large scale observational study that new or continued statin therapy in the first 24 h of the index AMI was associated with lower mortality compared with no statin use, but not with the incidence of recurrent MI.<sup>32</sup> Moreover, an association of prior statin use with smaller infarct size or better outcomes has been reported in patients with ischemic stroke.<sup>33,34</sup> Thus, it is possible that statin therapy is associated with reduced mortality by its limiting of tissue damage during ischemic events and subsequent invasive therapeutic procedures for the events.



### Characteristics of the Medical Therapy of the Study Patients

Despite the better survival of statin-treated patients, the present study also indicated suboptimal use of statins in Japanese high-risk patients during the study period. The use of ACEI, ARB and  $\beta$ -adrenergic blockers at hospital discharge was also less frequent than we expected from the data for the US and Europe<sup>27,35</sup>. The reported lower prevalence of CAD in Japan relative to the United States might cause underuse of preventive medical therapies<sup>25,26</sup>. However, the prevalence of CAD in the general population cannot explain the future risk of patients with established CAD. Because the patients analyzed in this study were a secondary prevention cohort with CAD, the use of statins in Japan was apparently suboptimal in 2000–2002.

The use of nitrates or calcium-channel blockers was much more frequent than in the reports from Europe analyzing patients after coronary revascularization<sup>27</sup>. This result agrees with a recent study of Japanese CAD patients.<sup>19</sup> Higher prevalence of coronary vasospastic angina in Japanese than in Caucasians may partly explain this difference.<sup>36</sup> Thus, our study patients had unique concomitant medical treatments in comparison with previous reports from Western countries,<sup>27</sup> and the results of the present study enable assessment of the consistency of the beneficial effects of statins in patient groups with distinctive backgrounds and concomitant medical therapy.

### Strengths and Limitations

The present study was based on data from the CREDO-Kyoto registry, a multicenter registry of 30 hospitals in Japan. The number of study patients was sufficient to assess the impact of each prognostic factor on mortality and the size of each participating hospital is variable. The data have been collected by trained clinical research coordinators based on a detailed manual and the follow-up rate was 96% at  $\geq 2$  years. Thus, the sample size, distribution of the size of the participating hospitals and the method of data acquisition strengthen the reliability of the data, and the results represent the “real world” clinical practice for CAD patients undergoing revascularization during 2000–2002 in Japan.

Several limitations that are common to all observational studies should be noted in the interpretation of the results. First, there were significant differences between the statin-treated and the statin-non-treated groups in many of the patients' baseline characteristics. Second, the statins and their doses were inconsistent and it is difficult to assess the efficacy of each statin at a particular dose, although the efficacies of statins may not be identical. Finally, the information about medical therapy was obtained at only 1 time point, hospital discharge, for each patient. Therefore, the adherence of the patients to the medications and the cross-over of patients between the statin-treated and the statin-non-treated groups have not been considered in the analyses. The lipid profiles of the patients before statin therapy are also uncertain, and the cholesterol levels without statin therapy might have been higher in the statin-treated group. Thus, the possibility that the results have been influenced by these factors cannot be eliminated.

### Conclusion

In the present study of Japanese patients undergoing their first coronary revascularization therapy, starting medical treatment with statins by hospital discharge was associated

with lower all-cause as well as cardiovascular mortality. The results can be seen as a rationale for the comprehensive use of statins for secondary prevention in patients with CAD.

### Acknowledgements

We are indebted to the clinical research coordinators (listed in Appendix 2) for their invaluable contributions to the data collection.

This work was supported in part by a Grant for Clinical Research for Evidence Based Medicine from the Ministry of Health, Labour and Welfare in Japan to T.K. and an educational grant from the Research Institute for Production Development (Kyoto, Japan).

### References

- Prasad A, Reeder G. Modern adjunctive pharmacotherapy of myocardial infarction. *Expert Opin Pharmacother* 2000; **1**: 405–418.
- Go AS, Iribarren C, Chandra M, Lathon PV, Fortmann SP, Quertermous T, et al. Statin and beta-blocker therapy and the initial presentation of coronary heart disease. *Ann Intern Med* 2006; **144**: 229–238.
- Group SSSS. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). *Lancet* 1994; **344**: 1383–1389.
- Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. *N Engl J Med* 1995; **333**: 1301–1307.
- Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. *N Engl J Med* 1996; **335**: 1001–1009.
- Investigators TPCABGT. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts: The Post Coronary Artery Bypass Graft Trial Investigators. *N Engl J Med* 1997; **336**: 153–162.
- Group TL-TIwPiDLs. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. *N Engl J Med* 1998; **339**: 1349–1357.
- Flaker GC, Warnica JW, Sacks FM, Moye LA, Davis BR, Rouleau JL, et al. Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations: Cholesterol and Recurrent Events (CARE) Investigators. *J Am Coll Cardiol* 1999; **34**: 106–112.
- Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. *Lancet* 2004; **364**: 685–696.
- Kinlay S, Schwartz GG, Olsson AG, Rifai N, Sasiela WJ, Szarek M, et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. *Circulation* 2004; **110**: 386–391.
- Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med* 2004; **350**: 1495–1504.
- Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial. *JAMA* 2002; **287**: 3215–3222.
- Arora R, Sowers JR, Saunders E, Probstfield J, Lazar HL. Cardioprotective strategies to improve long-term outcomes following coronary artery bypass surgery. *J Card Surg* 2006; **21**: 198–204.
- Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: Analysis of the Treating to New Targets study. *Lancet* 2006; **368**: 919–928.
- Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): A prospective randomised controlled trial. *Lancet* 2006; **368**: 1155–1163.
- Sakamoto T, Kojima S, Ogawa H, Shimomura H, Kimura K, Ogata

- Y, et al. Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. *Am J Cardiol* 2006; **97**: 1165–1171.
17. Sato H, Kinjo K, Ito H, Hirayama A, Nanto S, Fukunami M, et al. Effect of early use of low-dose pravastatin on major adverse cardiac events in patients with acute myocardial infarction: The OACIS-LIPID Study. *Circ J* 2008; **72**: 17–22.
  18. Nagashima M, Koyanagi R, Kasanuki H, Hagiwara N, Yamaguchi J, Atsuchi N, et al. Effect of early statin treatment at standard doses on long-term clinical outcomes in patients with acute myocardial infarction (the Heart Institute of Japan, Department of Cardiology Statin Evaluation Program). *Am J Cardiol* 2007; **99**: 1523–1528.
  19. Kohro T, Hayashi D, Okada Y, Yamazaki T, Nagai R. Effects of medication on cardiovascular events in the Japanese coronary artery disease (JCAD) study. *Circ J* 2007; **71**: 1835–1840.
  20. Kimura T, Morimoto T, Furukawa Y, Nakagawa Y, Shizuta S, Ehara N, et al. Long-term outcomes of coronary-artery bypass graft surgery versus percutaneous coronary intervention for multivessel coronary artery disease in the bare-metal stent era. *Circulation* 2008; **118**(Suppl): S199–S209.
  21. Serruys PW, Ong AT, van Herwerden LA, Sousa JE, Jatene A, Bonnier JJ, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: The final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. *J Am Coll Cardiol* 2005; **46**: 575–581.
  22. Rubin DB. Estimating causal effects from large data sets using propensity scores. *Ann Intern Med* 1997; **127**: 757–763.
  23. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. *Stat Med* 1998; **17**: 2265–2281.
  24. Brener SJ, Lytle BW, Casserly IP, Schneider JP, Topol EJ, Lauer MS. Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features. *Circulation* 2004; **109**: 2290–2295.
  25. Sekikawa A, Satoh T, Hayakawa T, Ueshima H, Kuller LH. Coronary heart disease mortality among men aged 35–44 years by prefecture in Japan in 1995–1999 compared with that among white men aged 35–44 by state in the United States in 1995–1998: Vital statistics data in recent birth cohort. *Jpn Circ J* 2001; **65**: 887–892.
  26. Sekikawa A, Ueshima H, Kadowaki T, El-Saed A, Okamura T, Takamiya T, et al. Less subclinical atherosclerosis in Japanese men in Japan than in White men in the United States in the post-World War II birth cohort. *Am J Epidemiol* 2007; **165**: 617–624.
  27. Schomig A, Mehilli J, Holle H, Hosl K, Kastrati D, Pache J, et al. Statin treatment following coronary artery stenting and one-year survival. *J Am Coll Cardiol* 2002; **40**: 854–861.
  28. Fox DJ, Kibiro M, Eichhofer J, Curzen NP. Patients undergoing coronary revascularisation: A missed opportunity for secondary prevention? *Postgrad Med J* 2005; **81**: 401–403.
  29. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: Results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. *Circulation* 2004; **110**: 674–678.
  30. Kinoshita M, Matsumura S, Sueyoshi K, Ogawa S, Fukuda K. Randomized trial of statin administration for myocardial injury: Is intensive lipid-lowering more beneficial than moderate lipid-lowering before percutaneous coronary intervention? *Circ J* 2007; **71**: 1225–1228.
  31. Pan W, Pinter T, Anton J, Lee VV, Vaughn WK, Collard CD. Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery. *Circulation* 2004; **110**(Suppl): II-45–II-49.
  32. Fonarow GC, Wright RS, Spencer FA, Fredrick PD, Dong W, Every N, et al. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. *Am J Cardiol* 2005; **96**: 611–616.
  33. Shook SJ, Gupta R, Vora NA, Tievsky AL, Katzan I, Krieger DW. Statin use is independently associated with smaller infarct volume in nonlacunar MCA territory stroke. *J Neuroimaging* 2006; **16**: 341–346.
  34. Alvarez-Sabin J, Huertas R, Quintana M, Rubiera M, Delgado P, Ribo M, et al. Prior statin use may be associated with improved stroke outcome after tissue plasminogen activator. *Stroke* 2007; **38**: 1076–1078.
  35. Daly CA, Clemens F, Sendon JL, Tavazzi L, Boersma E, Danchin N, et al. The initial management of stable angina in Europe, from the Euro Heart Survey: A description of pharmacological management and revascularization strategies initiated within the first month of presentation to a cardiologist in the Euro Heart Survey of Stable Angina. *Eur Heart J* 2005; **26**: 1011–1022.
  36. Pristipino C, Beltrame JF, Finocchiaro ML, Hattori R, Fujita M, Mongiardo R, et al. Major racial differences in coronary constrictor response between Japanese and Caucasians with recent myocardial infarction. *Circulation* 2000; **101**: 1102–1108.

## Appendix 1

### List of Participating Centers and Investigators

Jong-Dae Lee, Kuniyoshi Tanaka (Fukui University Hospital); Katsuo Okazaki (Fukuroi Municipal Hospital); Masaaki Takahashi, Teiji Oda (Hamamatsu Rosai Hospital); Shigeo Matsui, Naohiro Ohashi (Hikone Municipal Hospital); Eiichi Matsuyama, Makoto Kadoya (Himeji Medical Center); Yoshiki Takatsu, Shinichi Nomoto, Kazuaki Kataoka (Hyogo Prefectural Amagasaki Hospital); Hajime Kotoura, Masaki Aota, Akira Miura (Japanese Red Cross Society Wakayama Medical Center); Satoru Suwa (Juntendo University Shizuoka Hospital); Chuwa Tei, Ryuzo Sakata, Shuichi Hamasaki, Hiroyuki Yamamoto (Kagoshima University Medical and Dental Hospital); Takeshi Aoyama, Takahiro Sakurai (Kansai Electric Power Hospital); Mitsuo Matsuda, Masahiko Onoe, Yuzo Takeuchi (Kishiwada City Hospital); Ryuji Nohara, Kimisato Nakano (Kitano Hospital); Shigefumi Morioka, Yukikatsu Okada, Kenichi Shiratori, Yasuki Kihara, Michihiro Nasu (Kobe City Medical Center General Hospital); Satoshi Teramukai, Masanori Fukushima (Translational Research Informatics Center); Masakiyo Nobuyoshi, Hitoshi Okabayashi, Hitoshi Yasumoto, Jyota Nakano (Kokura Memorial Hospital); Tomoyuki Murakami, Katsuya Ishida (Koto Memorial Hospital); Hisao Ogawa, Michio Kawasaki, Seigo Sugiyama, Shoichiro Hagiwara (Kumamoto University Hospital); Kazuaki Mitsudo, Tatsuhiko Komiya, Kazushige Kadota (Kurashiki Central Hospital); Takeshi Kimura, Masashi Komeda, Yutaka Furukawa (Kyoto University Hospital); Takeshi Morimoto (Kyoto University Graduate School of Medicine); Ryozo Tatami, Teruaki Ushijima (Maizuru Kyosai Hospital); Akira Yoshida, Hiroyuki Nakajima, Shinji Miki (Mitsubishi Kyoto Hospital); Ryuichi Hattori, Noboru Nishiwaki, Manabu Shirota (Nara Hospital, Kinki University School of Medicine); Hiroshi Kato, Hiroshi Eizawa (Nishi-Kobe Medical Center); Masaru Tanaka, Kazuaki Minami (Osaka Red Cross Hospital); Minoru Horie, Tohru Asai, Hiroyuki Takashima, Ryuji Higashita (Shiga University of Medical Science Hospital); Mamoru Takahashi, Takafumi Tahata, Yoshiki Matoba (Shimabara Hospital); Kiyoshi Doyama, Makoto Araki (Shimada Municipal Hospital); Akinori Takizawa, Mitsuomi Shimamoto, Fumio Yamazaki (Shizuoka City Shizuoka Hospital); Osamu Doi, Hirofumi Kambara, Katsuhiko Matsuda, Satoshi Kaburagi, Masafumi Nara (Shizuoka General Hospital); Masaki Kawanami (Takanohara Central Hospital); Takashi Konishi, Kazunobu Nishimura, Seiji Ootani, Takaaki Sugita (Tenri Hospital)

## Appendix 2

### Clinical Research Coordinators

Kumiko Kitagawa, Hiromi Yoshida, Misato Yamauchi, Asuka Saeki, Chikako Hibi, Emi Takinami, Izumi Miki, Miya Hanazawa, Naoko Okamoto, Sachiko Maeda, Saeko Minematsu, Saori Tezuka, Yuki Sato, Yumika Fujino, Hitomi Sasae, Rei Fujita, Ayu Motofusa, Takami Hiraoka, Ayumi Yamamoto, Miho Hayashikawa, Yoko Fujiki.

## Antiplatelet Therapy and Stent Thrombosis After Sirolimus-Eluting Stent Implantation

Takeshi Kimura, MD; Takeshi Morimoto, MD; Yoshihisa Nakagawa, MD; Toshihiro Tamura, MD; Kazushige Kadota, MD; Hitoshi Yasumoto, MD; Hideo Nishikawa, MD; Yoshikazu Hiasa, MD; Toshiya Muramatsu, MD; Taiichiro Meguro, MD; Naoto Inoue, MD; Hidehiko Honda, MD; Yasuhiko Hayashi, MD; Shunichi Miyazaki, MD; Shigeru Oshima, MD; Takashi Honda, MD; Nobuo Shiode, MD; Masanobu Namura, MD; Takahito Sone, MD; Masakiyo Nobuyoshi, MD; Toru Kita, MD; Kazuaki Mitsudo, MD; for the j-Cypher Registry Investigators

**Background**—The influences of antiplatelet therapy discontinuation on the risk of stent thrombosis and long-term clinical outcomes after drug-eluting stent implantation have not yet been addressed adequately.

**Methods and Results**—In an observational study in Japan, 2-year outcomes were assessed in 10 778 patients undergoing sirolimus-eluting stent implantation. Data on status of antiplatelet therapy during follow-up were collected prospectively. Incidences of definite stent thrombosis were 0.34% at 30 days, 0.54% at 1 year, and 0.77% at 2 years. Thienopyridine use was maintained in 97%, 62%, and 50% of patients at 30 days, 1 year, and 2 years, respectively. Patients who discontinued both thienopyridine and aspirin had a significantly higher rate of stent thrombosis than those who continued both in the intervals of 31 to 180 days, 181 to 365 days, and 366 to 548 days after stent implantation (1.76% versus 0.1%,  $P<0.001$ ; 0.72% versus 0.07%,  $P=0.02$ ; and 2.1% versus 0.14%,  $P=0.004$ , respectively). When discontinuation of aspirin was taken into account, patients who discontinued thienopyridine only did not have an excess of stent thrombosis in any of the time intervals studied. Adjusted rates of death or myocardial infarction at 24 months were 4.1% for patients taking thienopyridine and 4.1% for patients not taking thienopyridine ( $P=0.99$ ) in the 6-month landmark analysis.

**Conclusions**—Discontinuation of both thienopyridine and aspirin, but not discontinuation of thienopyridine therapy only, was associated with an increased risk of stent thrombosis. Landmark analysis did not suggest an apparent clinical benefit of thienopyridine use beyond 6 months after sirolimus-eluting stent implantation. (*Circulation*. 2009;119:987-995.)

**Key Words:** aspirin ■ follow-up studies ■ stents ■ coronary disease ■ thrombosis

Concerns have been raised about the safety of drug-eluting stents (DES), and certain issues remain unresolved.<sup>1,2</sup> First, although premature discontinuation of antiplatelet therapy is reported to be the most powerful predictor of stent thrombosis (ST) and adverse cardiovascular outcomes,<sup>3-5</sup> the relative contribution of discontinuation of either aspirin or thienopyridine on ST rates has not been addressed adequately. Furthermore, the optimal duration of dual-antiplatelet therapy has not been well established, although dual-antiplatelet therapy beyond 1 year has become commonplace in clinical practice. To address these issues, a large-scale, multicenter

registry of patients undergoing sirolimus-eluting stent (SES) implantation was designed with prospective data collection on the status of antiplatelet therapy during follow-up.

### Clinical Perspective p 995

### Methods

#### Study Population

The j-Cypher registry is a physician-initiated prospective, multicenter observational study in Japan enrolling consecutive patients undergoing SES implantation. The relevant review boards in all 37

Received July 18, 2008; accepted November 30, 2008.

From the Department of Cardiovascular Medicine (T. Kimura, T.T., T. Kita) and Center for Medical Education and Clinical Epidemiology Unit (T. Morimoto), Graduate School of Medicine, Kyoto University, Kyoto, Japan; Division of Cardiology, Tenri Hospital (Y.N.), Tenri City, Japan; Division of Cardiology, Kurashiki Central Hospital (K.K., K.M.), Kurashiki, Japan; Division of Cardiology, Kokura Memorial Hospital (H.Y., M. Nobuyoshi), Kokura, Japan; Mie Heart Center (H.N.), Mie, Japan; Division of Cardiology, Tokushima Red Cross Hospital (Y. Hiasa), Komatsushima City, Japan; Division of Cardiology, Kawasaki Social Insurance Hospital (T. Muramatsu), Kawasaki City, Japan; Division of Cardiology, Sendai Health Hospital (T. Meguro, N.I., H.H.), Sendai, Japan; Division of Cardiology, Tsuchiya General Hospital (Y. Hayashi), Hiroshima, Japan; Division of Cardiology, National Cardiovascular Center (S.M.), Suita City, Japan; Division of Cardiology, Gunma Prefecture Cardiovascular Center (S.O.), Maebashi, Japan; Division of Cardiology, Saiseikai Kumamoto Hospital (T.H.), Kumamoto, Japan; Division of Cardiology, Matsue Red Cross Hospital (N.S.), Matsue, Japan; Division of Cardiology, Kanazawa Cardiovascular Hospital (M. Namura), Kanazawa, Japan; and Division of Cardiology, Ogaki Municipal Hospital (T.S.), Ogaki, Japan.

The online-only Data Supplement is available with this article at <http://circ.ahajournals.org/cgi/content/full/CIRCULATIONAHA.108.808311/DC1>. Correspondence to Takeshi Kimura, Department of Cardiovascular of Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507 Japan. E-mail [taketaka@kuhp.kyoto-u.ac.jp](mailto:taketaka@kuhp.kyoto-u.ac.jp)

© 2009 American Heart Association, Inc.

*Circulation* is available at <http://circ.ahajournals.org>

DOI: 10.1161/CIRCULATIONAHA.108.808311

**Table 1. Baseline Characteristics**

Patient Characteristics	
No. of patients	10 778
Age, y	68.3±10.2
Age ≥80 y, n (%)	1362 (13)
Male, n (%)	8123 (75)
Body mass index	23.9±3.4
Hypertension, n (%)	8069 (75)
Diabetes mellitus, n (%)	4400 (41)
Taking insulin	996 (9.2)
Current smoking, n (%)	2119 (20)
eGFR <30 mL·min <sup>-1</sup> ·1.73 m <sup>-2</sup> , n (%)	
Without hemodialysis	522 (5.1)
With hemodialysis	594 (5.5)
ACS, n (%)	2308 (21)
STEMI	733 (6.8)
Non-STEMI	220 (2.0)
Unstable angina	1355 (13)
Prior MI, n (%)	3024 (28)
Prior stroke, n (%)	1007 (9.3)
Peripheral vascular disease, n (%)	1276 (12)
Prior heart failure, n (%)	1460 (14)
Prior PCI, n (%)	5179 (48)
Prior CABG, n (%)	787 (7.3)
Multivessel disease, n (%)	5392 (50)
Target of unprotected LMCA, n (%)	419 (3.9)
Ejection fraction, %	58.1±13.4
No. of vessels treated	1.22±0.47
Multivessel stenting, n (%)	2089 (19)
No. of lesions treated	1.37±0.66
Total No. of stents	1.75±1.04
Total length of stents, mm	38.9±25.6
Lesion and procedural characteristics	
No. of lesions	14 811
Lesion location, n (%)	
LAD	6138 (42)
LCx	3130 (21)
RCA	4913 (33)
LMCA	499 (3.4)
Saphenous vein graft	109 (0.7)
In-stent restenosis, n (%)	1895 (13)
Chronic total occlusion, n (%)	1348 (9.1)
Severe calcification, n (%)	1311 (8.9)
Bifurcation lesion, n (%)	2857 (19)
Side-branch stenting, n (%)	479 (3.2)
Lesion length ≥30 mm, n (%)	2146 (15)
Preprocedural reference diameter <2.5 mm, n (%)	4196 (29)
Use of intravascular ultrasound, n (%)	6681 (45)
Direct stenting, n (%)	3416 (23)
After dilation, n (%)	6491 (44)
Maximum inflation pressure, atm	17.9±3.3
No. of stents used	1.29±0.57
Length of stents used, mm	28.6±15.3
Minimal stent size, mm	2.89±0.37

eGFR indicates estimated glomerular filtration rate; STEMI, ST-elevation MI; non-STEMI, non-ST-elevation MI; LMCA, left main coronary artery; LAD, left anterior descending coronary artery; LCx, left circumflex coronary artery; and RCA, right coronary artery.

Continuous variables are expressed as mean±SD.

**Table 2. Clinical Event Rates Through 2 Years**

	Cumulative Event Rate, %		
	30 d	1 y	2 y
Death	0.7	3.7	7.2
Cardiac death	0.6	2.2	3.7
Sudden death	0.02	0.7	1.4
MI	0.3	0.9	1.5
Related to ST	0.2	0.4	0.7
Stroke	0.4	1.8	3.1
ST			
Definite	0.34	0.54	0.77
Definite/probable	0.46	0.68	0.91
Definite/probable/possible	0.46	1.38	2.48
Target-lesion revascularization	0.5	6.9	10.2
CABG surgery	0.1	0.9	1.5
Any coronary revascularization	2.5	19.2	25.9

participating centers (online-only Data Supplement, Appendix I) approved the study protocol. Written informed consent was obtained from all patients.

In an attempt to evaluate penetration of SES and to secure enrollment of truly consecutive patients, all patients undergoing percutaneous coronary intervention (PCI) in each center during the study interval were recorded on the PCI screening list by the technical staff in the catheterization laboratories. When SES implantation was undertaken, each patient was invited to participate in the j-Cypher registry. Although data entry was basically left to the individual sites, the clinical research coordinators (online-only Data Supplement, Appendix II) in the data management center (Kyoto University Hospital, Department of Cardiology) supported data entry when necessary. Obvious inconsistencies were resolved by inquiries to the site investigators and/or by audits against the original data sources. Follow-up data were obtained from hospital charts or by contacting patients and/or referring physicians at 30 days, 6 months, and 1 year and yearly thereafter. When death, myocardial infarction (MI), and ST were reported, the events were adjudicated with use of the original source documents by a clinical events committee (online-only Data Supplement, Appendix II).

Between August 2004 and November 2006, 15 155 patients were enrolled in the registry from among 29 555 consecutive patients recorded on the PCI screening list. SES penetration varied markedly across centers, with a median penetration rate of 53% (range 16% to 92%). After the exclusion of 2331 patients who were registered repeatedly because of PCI for restenosis or new lesions, 12 824 patients were enrolled in the registry for the first time. Of 19 675 target lesions, 17 050 were treated exclusively with SES. Treatment for the remaining 2625 lesions included bare-metal stent (BMS; 1259 lesions), combination of SES and other stent types (495 lesions), other DES (60 lesions), nonstent PCI (672 lesions), and failed procedure (139 lesions). Ultimately, 10 778 patients (84%) treated with SES exclusively constituted the study population for the present analysis.

Complete 1-year follow-up (median of 491 days; interquartile range 387 to 730 days) was achieved in 96% of patients. At 1-year follow-up, information was collected from the hospital charts (75% of cases) or by contacting patients (25% of cases). Additional information was obtained from the referring physicians in 6% of cases.

## Definitions

Coronary angiographic parameters were assessed in each participating center either by visual assessment or by quantitative angio-